Astellas' Gastric Cancer Therapy Gets UK Regulator's Nod
Date
8/14/2024 3:43:28 PM
(MENAFN- Khaleej Times)
Published: Wed 14 Aug 2024, 3:45 PM
Last updated: Wed 14 Aug 2024, 3:46 PM
Britain's health regulator said on Wednesday it has approved Japan-based Astellas Pharma's therapy to treat a type of gastric cancer.
The monoclonal antibody, to be sold under brand name Vyloy, can recognise and attach itself to certain cancer cells to destroy them.
The regulator approved the therapy in combination with other anti-cancer medicines for adults with stomach or gastro-oesophageal junction cancer.
The gastro-oesophageal junction is where the oesophagus joins the stomach.
In January, the US Food and Drug Administration declined to approve the therapy, citing issues related to a third-party manufacturer.
The company has resubmitted its application, and the US health regulator is set to make its decision by November 9.
MENAFN14082024000049011007ID1108555984
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.